SCHEMBL18676293

SCHEMBL18676293

CN1CC(=O)N2Cc3[nH]c4ccccc4c3CC2C1=O

nearest known ligand 0.71

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.67
MEN1 O00255 3/20 0.67
KDM4E B2RXH2 1/20 0.60
ALDH1A1 P00352 1/20 0.60
MAPT P10636 1/20 0.60
HTT P42858 1/20 0.60
PDE5A O76074 6/20 0.56
TRPM8 Q7Z2W7 1/20 0.55
PDE11A Q9HCR9 1/20 0.53
PAX8 Q06710 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17520458 1.00 KMT2A (0.67) KMT2AMEN1KDM4EALDH1A1MAPT
SCHEMBL19248407 1.00 KMT2A (0.67) KMT2AMEN1KDM4EALDH1A1MAPT
SCHEMBL34472268 1.00 KMT2A (0.67) KMT2AMEN1KDM4EALDH1A1MAPT
SCHEMBL19161670 0.85 KMT2A (0.77) KMT2AMEN1KDM4EALDH1A1MAPT
SCHEMBL19138900 0.85 KMT2A (0.77) KMT2AMEN1KDM4EALDH1A1MAPT
SCHEMBL19161254 0.84 KMT2A (0.73) KMT2AMEN1KDM4EALDH1A1MAPT
SCHEMBL19138937 0.84 KMT2A (0.73) KMT2AMEN1KDM4EALDH1A1MAPT
SCHEMBL11884302 0.84 KMT2A (0.63) KMT2AMEN1KDM4EALDH1A1MAPT
SCHEMBL17520545 0.84 KMT2A (0.61) KMT2AMEN1KDM4EALDH1A1MAPT
SCHEMBL19138994 0.84 KMT2A (0.61) KMT2AMEN1KDM4EALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3177621-B1 NOVEL HDAC6 INHIBITORS AND THEIR USES UNIV REGENSBURG (DE) 2021-11-10 EP disclosed
US-10106540-B2 HDAC6 inhibitors and their uses UNIVERSITÄT REGENSBURG (DE) 2018-10-23 US disclosed
EP-3301095-A1 NOVEL PHOSPHODIESTERASE TYPE-5 INHIBITOR AND APPLICATION THEREOF Chongqing University Of Arts And Sciences (CN) 2018-04-04 EP disclosed
US-20170210743-A1 NOVEL HDAC6 INHIBITORS AND THEIR USES Universitätsklinikum Jena (DE) 2017-07-27 US disclosed
EP-2637664-B1 COMPOSITIONS AND METHODS OF TREATING PULMONARY HYPERTENSION GILEAD SCIENCES INC (US) 2017-03-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170210743-A1 NOVEL HDAC6 INHIBITORS AND THEIR USES HDAC6, HDAC5, HDAC4 KMT2A 74/4885MEN1 3320/4885KDM4E 676/4885
US-10106540-B2 HDAC6 inhibitors and their uses HDAC6, HDAC5, HDAC4 KMT2A 69/4885MEN1 3150/4885KDM4E 608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.